Amsterdam, The Netherlands , July 22, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a...
Leiden, The Netherlands, 19 July 2021 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral...
Leiden, The Netherlands, June 30, 2021 – Azafaros B.V. today announced that Stefano Portolano, M.D., has joined Azafaros as Chief Executive Officer (CEO) and has concurrently been appointed to the Board of Directors of the company. Dr. Portolano is an experienced...
AMSTERDAM, NETHERLANDS – June 29, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today...
Amsterdam, The Netherlands, 15 June 2021 – VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the...
Leiden, The Netherlands, 15 June 2021 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jan Öhrström, as Chief Executive Officer, and of Dr. Alex Gold to...
